SM
KYTH

Sabby Management’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

Sabby Management’s Portfolio KYTH Stock Details KYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-66,200
Closed -$2.47M – 301
2013
Q4 		$2.47M Buy
+66,200
New +$2.75M 0.16% 72

Other funds holding KYTH

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sabby Management's KYTH Position: Q1 2014 in Review

Sabby Management sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q1 2014, closing a stake of 66,200 shares — an estimated $2.47M sold.

Sabby Management first reported a position in KYTH in Q4 2013 and held it in 1 quarter. The position peaked at $2.47M in Q4 2013. 102 funds tracked by Wall St. Rank hold KYTH as of Q1 2014.

  • Sabby Management reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q1 2014 after selling out during the quarter.
  • Sabby Management sold 66,200 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q1 2014, an estimated $2.47M.
  • Sabby Management first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q4 2013 and held it in 1 quarter.
  • Sabby Management's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $2.47M in Q4 2013.
  • 102 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q1 2014.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.